RLYB
Health check
See the tests
- ✗Positive net income
- ✗Positive operating cash flow
- ✓Return on assets improved
- ✗Cash flow above net income
- ✓Long-term debt / assets fell
- ✓Current ratio improved
- ✗No share dilution
- ✗Gross margin improved
- ✓Asset turnover improved
Computed by Coteau from the company's SEC filings (latest balance sheet Jun 30, 2026). Descriptive, not a forecast.
Live chart
What they do
Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial.
For information only · Important disclosures
Grades vs sector
No sector grades for RLYB yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.
Systematic Models
Not held by any of our 5 live models right now.
News
More newsKey stats
Valuation and fundamentals
Valuation & fundamentals
Discounted cash flow
A DCF starts from trailing free cash flow, so it can overstate value if the last 12 months were unusually strong (or weak). Use the bear case or edit the starting cash flow if so.
Edit assumptions · recalculates instantly
Free cash flow = operating cash flow − capital spending, trailing 12 months (TTM to 2026-06-30). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta 1.00 (n/a) × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.
Multiples vs sector
Quality & financial health
Piotroski F-score 4/9 · last two fiscal years
Analysts
Annual history
| FY | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | $858.0K | $-9.0M | $-29.8M |
| 2024 | $636.0K | $-57.8M | $-49.3M |
From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR –.
Earnings
RLYB earningsNo upcoming date on fileIn line = within 1% of the estimate.
Insider trades
–
–
–
–
–
–
–
–
Stats refreshed 2026-10-21 18:00:26 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now
Free to use. No card, no ads, no auto-renew.
Independent research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app
Beta 0.9 · Oct 21, 2026